Publications
Specialty
Search
Wounds, Wound Care
09/24/2024
Objective: To evaluate the use of cadaveric skin graft and subsequent autologous split-thickness skin graft (STSG) in the management of wounds of diverse etiologies at a single institution.
Veterans Health Today
09/24/2024
New research supports the use of adjuvant platinum chemotherapy after radical nephroureterectomy in patients with upper tract urothelial carcinoma (UTUC) with high-risk features. This research was published in the Journal of Clinical Oncology.
Journal of Clinical Pathways
09/24/2024
Study reveals aggressive and immunosuppressive features of uterine serous carcinoma tumors in Black patients, highlighting potential for targeted therapeutic strategies to address disparities in patient outcomes.
Wound Care
09/24/2024
A 120-patient RCT will examine the efficacy of porcine placental extracellular matrix as an adjunct to SoC vs SoC alone for hard-to-heal VLUs with the primary outcome being percentage of ulcer closure at 12 weeks. Not yet recruiting; estimated study completion is April 2026. clinicaltrials.gov
Wound Care
09/24/2024
Cork Medical received an updated FDA 510(k) clearance for their VERSA NPWT system. The updated clearance has the same indication but expands the use to both healthcare facilities and home use environments, as well as making updates to display and IFU.
Wound Care
09/24/2024
MiMedx initiated a 170-patient study to evaluate 2 human amnion/chorion membrane (ppLHACM) products, EPIEFFECT and EPIXPRESS and SoC vs SoC alone in the treatment of non-healing DFUs. Primary outcome measures complete healing in 12 wks. Estimated study completion is August 2026. clinicaltrials.gov
Wound Care
09/24/2024
A 20-patient pilot clinical trial will evaluate the use of borate-based bioactive glass fiber matrix (Mirragen) for treatment of DFUs with primary outcome of complete wound closure at 12 weeks. Not yet recruiting; estimated study completion is Oct 2025. clinicaltrials.gov
Wound Care
09/24/2024
Guard Medical received FDA 510(k) clearance for its NPseal NPWT device for larger incisions, using its previous devices as a predicate. The NPseal 20 and the NPseal 25 are designed for surgically closed incisions up to 20 cm and 25 cm.
Wound Care
09/24/2024
Biogennix introduces its new Agilon Surgical Matrix for wounds derived from bovine Type 1 collagen. Upon contact with a new or open wound, it transforms into a gel that maintains a moist, low pH environment and helps form tissue and epithelialization for enhanced wound healing. ODT
Wound Care
09/24/2024
A comparison study found StrataGraft significantly reduced inpatient length of stay (4.84 days) vs autografts in adults with deep partial-thickness burns. Results translate into reduced burden on the healthcare system and lower costs for inpatient burn treatment with clinical benefits for patients. Clinico
Wound Care
09/24/2024
CMS has published the Oct-Dec 2024 quarterly drug pricing files with payment limits for some Part B-covered drugs. A total of 104 skin substitute products had a published ASP, adding 11 new codes. Of these, 9 products had ASPs over $2K and 2 products had ASPs over $3K.
Neurology
09/24/2024
Test your knowledge of recent research with this quiz!
Oncology
09/24/2024
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
ePlasty
09/24/2024
Sulfur mustard toxicity involves DNA alkylation, protein damage, and oxidative stress. Clinical features include skin, eye, and respiratory injuries. Treatment focuses on decontamination, supportive care, and symptom management. Long-term effects include cancer risk, respiratory issues, and chronic skin conditions.
Oncology
09/24/2024
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer after progressing on or after CDK4/6 inhibition.
The Dermatologist
09/24/2024
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
ePlasty
09/24/2024
Jubril Adepoju, BS; John A. Toms III, MS; Elizabeth S. O’Neill, MD, MPH; Mark Grevious, MD, MBA; Jafar Hasan, MD, MBA; Christina Tragos, MD; Matthew Doscher, MD, FACS
In the article Adepoju J, Toms JA 3rd, O'Neill ES, et al. Mixed neuroendocrine-squamous cell carcinoma of the hand with metastatic dissemination: A case report. Eplasty. 2024;24:e45. Published 2024 Aug 15, the fourth author’s name was spelled incorrectly as Mark Grievous. The correct spelling is Mark Grevious. The online article has been updated to reflect this change.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
09/24/2024
“Our results provide robust evidence that health insurance not only improves mental health, as the original study has found, but also improves physical health, such as lowering blood pressure,” said Dr. Yusuke Tsugawa.
Advances in Inflammatory Bowel Disease Network
09/24/2024
A recent study revealed upadacitinib significantly improved clinical and endoscopic outcomes, even among patients with prior biologic failure.
Pharmacy Learning Network
09/23/2024
Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus (PIV) are associated with severe respiratory disease requiring augmented oxygenation or ventilation in general hospitalized patients, according to a study published in the Journal of Hospital Medicine.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
